The study will be presented at the annual meeting of the American Society for Radiation Oncology (ASTRO).
"Our
study evaluated the skin toxicity and early cardiac toxicity of
concurrent Trastuzumab and radiation therapy treatment in the adjuvant
setting," says Penny Anderson, M.D., radiation oncologist at Fox Chase
and lead author on the study. "We found that there was an extremely low
rate of acute radiation dermatitis and cardiac toxicity in patients who
received this type of treatment."
The study followed 85 breast
cancer patients who received adjuvant Trastuzumab while also receiving a
course of adjuvant radiation therapy, as well as 85 breast cancer
patients who only received adjuvant radiation therapy. Acute dermatitis
was grade 2 in 15% and grade 3 in 2% of the patients receiving
concurrent treatment, likewise grade 2 and grade 3 dermatitis was
observed in 14% and 2 % of patients only receiving radiation
therapy--there was only one patient who developed a grade > 2. There
were no differences in cardiac toxicity between the two groups.
"The results
of this study show that it is safe to use both Trastuzumab and radiation
therapy in an adjuvant setting, when clinically indicated," adds
Anderson. "We would like to see longer follow-up to evaluate the
potential differences in late cardiac toxicity." Adapted from materials provided by Fox Chase Cancer Center, via EurekAlert!, a service of AAAS.
Terramed Alliance is a non-profit charity organization
dedicated to research, education and advocacy of breast cancer. One of
the vision of Terramed Alliance is to provide this community and
Internet users with a charity based research and education entity.
Advocacy of breast cancer through education is vital to the reduction of
this disease. For any requests and enquiries, please contact at us: cancer@terramedalliance.us www.terramedalliance.us
No comments:
Post a Comment